Characteristics of arbidol-resistant mutants of influenza virus : Implications for the mechanism of anti-influenza action of arbidol
Identifieur interne : 000046 ( PascalFrancis/Curation ); précédent : 000045; suivant : 000047Characteristics of arbidol-resistant mutants of influenza virus : Implications for the mechanism of anti-influenza action of arbidol
Auteurs : Irina A. Leneva [Royaume-Uni, Russie] ; Rupert J. Russell [Royaume-Uni] ; Yury S. Boriskin [Russie] ; Alan J. Hay [Royaume-Uni]Source :
- Antiviral research [ 0166-3542 ] ; 2009.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
The antiviral drug arbidol (ARB), which is licensed in Russia for use against influenza, is known to inhibit early membrane fusion events in influenza A and B virus replication. To investigate in more detail the target and mechanism of ARB action we generated and studied the characteristics of ARB-resistant influenza virus mutants. Observations of the ARB susceptibility of reassortants between A/Singapore/l/57(H2N2) and A/chicken/Germany/27(H7N7, "Weybridge" strain) and of mutants of the latter virus identified the virus haemagglutinin (HA) as the major determinant of ARB sensitivity. ARB-resistant mutants, selected from the most sensitive reassortant, possessed single amino acid substitutions in the HA2 subunit which caused an increase in the pH of fusion and the associated conformational change in HA. ARB was shown to stabilize the HA by causing a 0.2 pH unit reduction in the pH of the transition to the low pH form, which was specifically abrogated by the resistance mutations. Some of the resistance mutations, which reduce acid stability and would disrupt ARB-HA interactions, are located in the vicinity of a potential ARB binding site identified using the docking programme Gold. Together, the results of these investigations indicate that ARB falls within a class of inhibitor which interacts with HA to stabilize it against the low pH transition to its fusogenic state and consequently inhibit HA-mediated membrane fusion during influenza virus infection.
| pA |
|
|---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000028
Links to Exploration step
Pascal:09-0131606Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Characteristics of arbidol-resistant mutants of influenza virus : Implications for the mechanism of anti-influenza action of arbidol</title><author><name sortKey="Leneva, Irina A" sort="Leneva, Irina A" uniqKey="Leneva I" first="Irina A." last="Leneva">Irina A. Leneva</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>National Institute for Medical Research, Mill Hill</s1><s2>London NW7 1AA</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Centre of Drug Chemistry, Russian Chemical and Pharmaceutical Institute</s1><s2>Moscow</s2><s3>RUS</s3><sZ>1 aut.</sZ></inist:fA14><country>Russie</country></affiliation></author><author><name sortKey="Russell, Rupert J" sort="Russell, Rupert J" uniqKey="Russell R" first="Rupert J." last="Russell">Rupert J. Russell</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>School of Biology, University of St Andrews</s1><s2>Fife Ky16 9ST</s2><s3>GBR</s3><sZ>2 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Boriskin, Yury S" sort="Boriskin, Yury S" uniqKey="Boriskin Y" first="Yury S." last="Boriskin">Yury S. Boriskin</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Institute of Virology, Russian Medical Academy of Sciences</s1><s2>Moscow</s2><s3>RUS</s3><sZ>3 aut.</sZ></inist:fA14><country>Russie</country></affiliation></author><author><name sortKey="Hay, Alan J" sort="Hay, Alan J" uniqKey="Hay A" first="Alan J." last="Hay">Alan J. Hay</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>National Institute for Medical Research, Mill Hill</s1><s2>London NW7 1AA</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">09-0131606</idno><date when="2009">2009</date><idno type="stanalyst">PASCAL 09-0131606 INIST</idno><idno type="RBID">Pascal:09-0131606</idno><idno type="wicri:Area/PascalFrancis/Corpus">000028</idno><idno type="wicri:Area/PascalFrancis/Curation">000046</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Characteristics of arbidol-resistant mutants of influenza virus : Implications for the mechanism of anti-influenza action of arbidol</title><author><name sortKey="Leneva, Irina A" sort="Leneva, Irina A" uniqKey="Leneva I" first="Irina A." last="Leneva">Irina A. Leneva</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>National Institute for Medical Research, Mill Hill</s1><s2>London NW7 1AA</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Centre of Drug Chemistry, Russian Chemical and Pharmaceutical Institute</s1><s2>Moscow</s2><s3>RUS</s3><sZ>1 aut.</sZ></inist:fA14><country>Russie</country></affiliation></author><author><name sortKey="Russell, Rupert J" sort="Russell, Rupert J" uniqKey="Russell R" first="Rupert J." last="Russell">Rupert J. Russell</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>School of Biology, University of St Andrews</s1><s2>Fife Ky16 9ST</s2><s3>GBR</s3><sZ>2 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author><author><name sortKey="Boriskin, Yury S" sort="Boriskin, Yury S" uniqKey="Boriskin Y" first="Yury S." last="Boriskin">Yury S. Boriskin</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Institute of Virology, Russian Medical Academy of Sciences</s1><s2>Moscow</s2><s3>RUS</s3><sZ>3 aut.</sZ></inist:fA14><country>Russie</country></affiliation></author><author><name sortKey="Hay, Alan J" sort="Hay, Alan J" uniqKey="Hay A" first="Alan J." last="Hay">Alan J. Hay</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>National Institute for Medical Research, Mill Hill</s1><s2>London NW7 1AA</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>Royaume-Uni</country></affiliation></author></analytic><series><title level="j" type="main">Antiviral research</title><title level="j" type="abbreviated">Antivir. res.</title><idno type="ISSN">0166-3542</idno><imprint><date when="2009">2009</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Antiviral research</title><title level="j" type="abbreviated">Antivir. res.</title><idno type="ISSN">0166-3542</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral</term><term>Arbidol</term><term>Conformation</term><term>Fusion inhibitor</term><term>Hemagglutinin</term><term>Influenzavirus</term><term>Mechanism of action</term><term>Membrane fusion</term><term>Mutation</term><term>Resistance</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Inhibiteur de fusion</term><term>Résistance</term><term>Mutation</term><term>Influenzavirus</term><term>Mécanisme action</term><term>Hémagglutinine</term><term>Conformation</term><term>Fusion membranaire</term><term>Antiviral</term><term>Arbidol</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The antiviral drug arbidol (ARB), which is licensed in Russia for use against influenza, is known to inhibit early membrane fusion events in influenza A and B virus replication. To investigate in more detail the target and mechanism of ARB action we generated and studied the characteristics of ARB-resistant influenza virus mutants. Observations of the ARB susceptibility of reassortants between A/Singapore/l/57(H2N2) and A/chicken/Germany/27(H7N7, "Weybridge" strain) and of mutants of the latter virus identified the virus haemagglutinin (HA) as the major determinant of ARB sensitivity. ARB-resistant mutants, selected from the most sensitive reassortant, possessed single amino acid substitutions in the HA2 subunit which caused an increase in the pH of fusion and the associated conformational change in HA. ARB was shown to stabilize the HA by causing a 0.2 pH unit reduction in the pH of the transition to the low pH form, which was specifically abrogated by the resistance mutations. Some of the resistance mutations, which reduce acid stability and would disrupt ARB-HA interactions, are located in the vicinity of a potential ARB binding site identified using the docking programme Gold. Together, the results of these investigations indicate that ARB falls within a class of inhibitor which interacts with HA to stabilize it against the low pH transition to its fusogenic state and consequently inhibit HA-mediated membrane fusion during influenza virus infection.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0166-3542</s0></fA01><fA02 i1="01"><s0>ARSRDR</s0></fA02><fA03 i2="1"><s0>Antivir. res.</s0></fA03><fA05><s2>81</s2></fA05><fA06><s2>2</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Characteristics of arbidol-resistant mutants of influenza virus : Implications for the mechanism of anti-influenza action of arbidol</s1></fA08><fA11 i1="01" i2="1"><s1>LENEVA (Irina A.)</s1></fA11><fA11 i1="02" i2="1"><s1>RUSSELL (Rupert J.)</s1></fA11><fA11 i1="03" i2="1"><s1>BORISKIN (Yury S.)</s1></fA11><fA11 i1="04" i2="1"><s1>HAY (Alan J.)</s1></fA11><fA14 i1="01"><s1>National Institute for Medical Research, Mill Hill</s1><s2>London NW7 1AA</s2><s3>GBR</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></fA14><fA14 i1="02"><s1>Centre of Drug Chemistry, Russian Chemical and Pharmaceutical Institute</s1><s2>Moscow</s2><s3>RUS</s3><sZ>1 aut.</sZ></fA14><fA14 i1="03"><s1>School of Biology, University of St Andrews</s1><s2>Fife Ky16 9ST</s2><s3>GBR</s3><sZ>2 aut.</sZ></fA14><fA14 i1="04"><s1>Institute of Virology, Russian Medical Academy of Sciences</s1><s2>Moscow</s2><s3>RUS</s3><sZ>3 aut.</sZ></fA14><fA20><s1>132-140</s1></fA20><fA21><s1>2009</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>18839</s2><s5>354000186471650050</s5></fA43><fA44><s0>0000</s0><s1>© 2009 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>1 p.</s0></fA45><fA47 i1="01" i2="1"><s0>09-0131606</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Antiviral research</s0></fA64><fA66 i1="01"><s0>NLD</s0></fA66><fC01 i1="01" l="ENG"><s0>The antiviral drug arbidol (ARB), which is licensed in Russia for use against influenza, is known to inhibit early membrane fusion events in influenza A and B virus replication. To investigate in more detail the target and mechanism of ARB action we generated and studied the characteristics of ARB-resistant influenza virus mutants. Observations of the ARB susceptibility of reassortants between A/Singapore/l/57(H2N2) and A/chicken/Germany/27(H7N7, "Weybridge" strain) and of mutants of the latter virus identified the virus haemagglutinin (HA) as the major determinant of ARB sensitivity. ARB-resistant mutants, selected from the most sensitive reassortant, possessed single amino acid substitutions in the HA2 subunit which caused an increase in the pH of fusion and the associated conformational change in HA. ARB was shown to stabilize the HA by causing a 0.2 pH unit reduction in the pH of the transition to the low pH form, which was specifically abrogated by the resistance mutations. Some of the resistance mutations, which reduce acid stability and would disrupt ARB-HA interactions, are located in the vicinity of a potential ARB binding site identified using the docking programme Gold. Together, the results of these investigations indicate that ARB falls within a class of inhibitor which interacts with HA to stabilize it against the low pH transition to its fusogenic state and consequently inhibit HA-mediated membrane fusion during influenza virus infection.</s0></fC01><fC02 i1="01" i2="X"><s0>002B02S05</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Inhibiteur de fusion</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Fusion inhibitor</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Inhibidor fusión</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Résistance</s0><s5>03</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Resistance</s0><s5>03</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Resistencia</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Mutation</s0><s5>04</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Mutation</s0><s5>04</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Mutación</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Influenzavirus</s0><s2>NW</s2><s5>05</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Influenzavirus</s0><s2>NW</s2><s5>05</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Influenzavirus</s0><s2>NW</s2><s5>05</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Mécanisme action</s0><s5>06</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Mechanism of action</s0><s5>06</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Mecanismo acción</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Hémagglutinine</s0><s5>08</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Hemagglutinin</s0><s5>08</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Hemoaglutinina</s0><s5>08</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Conformation</s0><s5>10</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Conformation</s0><s5>10</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Conformación</s0><s5>10</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Fusion membranaire</s0><s5>12</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Membrane fusion</s0><s5>12</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Fusión membranaria</s0><s5>12</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Antiviral</s0><s5>26</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Antiviral</s0><s5>26</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Antiviral</s0><s5>26</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Arbidol</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Arbidol</s0><s4>CD</s4><s5>96</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Orthomyxoviridae</s0><s2>NW</s2></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Orthomyxoviridae</s0><s2>NW</s2></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Orthomyxoviridae</s0><s2>NW</s2></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Virus</s0><s2>NW</s2></fC07><fN21><s1>096</s1></fN21></pA></standard></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000046 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000046 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:09-0131606
|texte= Characteristics of arbidol-resistant mutants of influenza virus : Implications for the mechanism of anti-influenza action of arbidol
}}
| This area was generated with Dilib version V0.6.33. |  |